Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples